StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report published on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their price target on shares of Trevena from $9.00 to $5.00 and set a buy rating on the stock in a research note on Thursday, May 16th.

Trevena Stock Performance

Shares of TRVN opened at $0.23 on Friday. The company has a market cap of $4.14 million, a price-to-earnings ratio of -0.08 and a beta of 1.06. The stock has a fifty day moving average price of $0.30 and a two-hundred day moving average price of $0.44. Trevena has a 52-week low of $0.19 and a 52-week high of $1.12.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01. The business had revenue of $0.02 million during the quarter. As a group, research analysts predict that Trevena will post -1.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC bought a new stake in shares of Trevena, Inc. (NASDAQ:TRVN) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena at the end of the most recent quarter. Institutional investors and hedge funds own 13.56% of the company’s stock.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.